What is Foresight Diagnostics?
Foresight Diagnostics operates at the vanguard of molecular oncology, specializing in the development of advanced liquid biopsy testing platforms. The company's core technology is engineered to measure minimal residual disease (MRD) with unprecedented precision, achieving detection limits below 0.0001%. This technical capability provides physicians and biopharmaceutical partners with actionable, high-fidelity data, facilitating more personalized and effective treatment paradigms for cancer patients.
By bridging the gap between complex genomic data and clinical decision-making, Foresight Diagnostics addresses a significant unmet need in the healthcare market. Its platform is designed for broad applicability across various cancer types, ensuring that the company remains a central figure in the shift toward data-driven, personalized oncology care.
How much funding has Foresight Diagnostics raised?
Foresight Diagnostics has raised a total of $104.3M across 3 funding rounds:
Series A
$12.5M
Series B
$58.8M
Series B
$33M
Series A (2021): $12.5M with participation from Bluebird Ventures, Pear Ventures, and Civilization Ventures
Series B (2023): $58.8M led by Foresite Capital, Pear Ventures, and Bluebird Ventures
Series B (2024): $33M supported by Civilization Ventures, Stanford University, Bluebird Ventures, Pear VC, Foresite Capital, and Agent Capital
Key Investors in Foresight Diagnostics
Foresite Capital
A multi-stage investment firm that leverages data science to identify and fund breakthrough opportunities at the intersection of biotechnology and big data.
Civilization Ventures
A venture capital firm focused on health tech and biopharma, specializing in preventative and personalized healthcare solutions with a strong track record in genomics.
Agent Capital
A healthcare-focused venture firm that collaborates with scientists and entrepreneurs to advance novel therapeutics and diagnostics in oncology and rare diseases.
What's next for Foresight Diagnostics?
With the recent influx of capital, Foresight Diagnostics is well-positioned to accelerate its clinical validation programs and expand its commercial footprint. The strategic focus will likely center on scaling the deployment of its MRD testing platform, deepening partnerships with biopharmaceutical entities, and refining its data science capabilities to further enhance diagnostic accuracy. As the company moves deeper into its growth phase, the emphasis will remain on translating its superior sensitivity metrics into improved patient outcomes and establishing a dominant market position in the competitive liquid biopsy landscape.
See full Foresight Diagnostics company page
